-
Pegaptanib
- indication:For the treatment of neovascular (wet) age-related macular degeneration.
- pharmacologypharmacology:
- mechanism: Pegaptanib binds to the major pathological VEGF isoform, extracellular VEGF165, thereby inhibiting VEGF165 binding to its VEGF receptors. The inhibition of VEGF164, the rodent counterpart of human VEGF165, was effective at suppressing pathological neovascularization.
- toxicity:
- absorprion: In animals, pegaptanib is slowly absorbed into the systemic circulation from the eye after intravitreous administration.
- halflife: In humans, after a 3 mg monocular dose (10 times the recommended dose), the average (± standard deviation) apparent plasma half-life of pegaptanib is 10 (± 4) days.
- roouteelimination:
- volumedistribution:
- clearance: